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Abstract Human cysticercosis (CC) is a parasitic zoonosis
caused by the larval stage (cyst) of the Taenia solium. Cysts
can establish in the human central nervous system
(neurocysticercosis, NCC) and other organs and tissues; they
also develop in pigs, the natural intermediate host. Human
taeniosis may be caused by T. solium, Taenia saginata and
Taenia asiatica tapeworms; these infections are usually
asymptomatic, but show a significant relevance as they per-
petuate the parasites’ life cycle, and, in the case of T. solium,
they are the origin of (N)CC. In European Union (EU) mem-
ber states and associated countries, the occurrence of autoch-
thonous T. solium cases is debated, and imported cases have
significantly increased lately; the status of T. asiatica has been
never reported, whereas T. saginata is prevalent and causes an
economic impact due to condemned carcasses. Based on their
effects on the EU society, the specific diagnosis of these pa-
thologies is relevant for their prevention and control. The aims
of this study were to know the diagnostic tests used in
European laboratories for human taeniosis/cysticercosis by
means of a questionnaire, to determine potential gaps in their
detection, and to obtain preliminary data on the number of
diagnosed taeniosis/CC cases.
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Introduction
Human cysticercosis (CC) is a zoonotic parasitic infection
caused by the larval stage (metacestode, cysticercus) of the
pork tapeworm Taenia solium, formerly named Cysticercus
cellulosae. These cysticerci establish in the human central
nervous system (neurocysticercosis, NCC), eye, muscle,
and, in rare cases, other tissues, and are a major cause of
epilepsy in endemic low-income countries [1]. NCC is con-
sidered to be the most common helminth infection of the hu-
man nervous system [1, 2]. Humans acquire CC by ingesting
T. solium eggs, released by themselves (auto- or self-infection)
or by another tapeworm carrier [2], through fecal-oral contam-
ination [3–6]. Humans are the unique T. solium definitive host
(taeniosis), acquiring the infection by eating raw or
undercooked pork harboring cysticerci; pigs are the natural
intermediate host developing cysticerci by ingesting parasite
eggs (porcine cysticercosis) on human feces. Themaintenance
of the life cycle requires a close association between humans
and pigs [7]. Human taeniosis may also be caused by Taenia
saginata and Taenia asiatica [8], of which the cysticerci only
establish in cattle and pigs, respectively. So far, CC caused by
T. saginata and T. asiatica has never been reported in humans.
Human CC occurs globally and continues to cause serious
health problems [9]. The highest rates of T. soliumCC are found
in areas of Latin America, Asia, and sub-Saharan Africa with
poor sanitation and free-ranging pigs that have access to human
feces [10, 11]. In the European Union member states and asso-
ciated countries (henceforth EU), T. solium was endemic in the
past, although recent publications suggest that autochthonous
cases may still be possible in some regions [12–14]. In recent
years, imported CC cases have increased in parallel to the in-
creased migration and travel [15]. Human taeniosis is not asso-
ciated with major clinical symptoms, but has significant impli-
cations as it perpetuates the parasites’ life cycle, and, in the case
of T. solium, causes a risk of NCC in the tapeworm carriers and
people in their environment. T. solium infection is consistently
classified as the most relevant food-borne parasite worldwide
[16, 17]. T. saginata causes economic loss in the bovine meat
sector due to condemned carcasses [18, 19].
Based on its rather rare occurrence in the EU, NCC is a
challenge for care providers. NCC clinical manifestations are
pleomorphic, varied and nonspecific, being related to individ-
ual differences in the number, size, location, stage of the par-
asite(s) and in the severity of the host’s immune response to
the parasite. Although no pathognomonic clinical picture ex-
ists, in endemic regions new onset epileptic seizures and pro-
gressive crescendo headache are highly suggestive of NCC. In
non-endemic regions, the diagnosis of NCC is primarily based
on neuroimaging, and confirmed/aided by serology [20, 21],
whereas the detection of taeniosis is most commonly made by
stool microscopic examination (Taenia genus specific).
Nevertheless, the early and species-specific identification of
the taeniid and subsequent adapted management is crucial to
avoid not only human-to-human transmission, but also hu-
man-to-pig/cattle transmission. New diagnostic tools [22],
more specific and sensitive (immunological and molecular
assays), have recently been developed for taeniosis and cysti-
cercosis, however they are not yet commercially available/
widely used.
Therefore, the knowledge of the in vitro diagnostic tools
used in the EU for the detection of taeniosis/cysticercosis and
their performances, as well as the identification/mapping of
EU laboratories carrying out specific diagnosis of the disease,
is of particular importance for the control, management and
surveillance of these parasitic diseases.
The overall aim of the present study was to find out more
about the diagnostic tests used in EU laboratories for human
taeniosis/cysticercosis bymeans of a questionnaire in order to:
(i) identify the assays offered for their examination, (ii) deter-
mine potential gaps in the techniques used by comparison
with recently developed tools, and (iii) have some preliminary
data on the number of taeniosis and CC cases diagnosed in the
laboratories of different EU countries. In the present work,
with the term taeniosis, we refer only to infections caused by
cestodes of the genus Taenia.
Materials and methods
Participants
CYSTINET, the European Network on Taeniosis/Cysticercosis,
consists of 27 EU countries, two EU Associated countries
(Norway and Switzerland), one country (Serbia) that initiated
the Stabilization and Association Process, one country (the for-
mer Yugoslav Republic of Macedonia [FYROM]) that is a can-
didate for accession to EU, six international partner countries and
the World Health Organization (WHO) as specific organization
(http://www.cost.eu), corresponds to the COSTAction TD1302
(http://www.cystinet.org/). All CYSTINET members were
invited via e-mail and orally at two CYSTINET meetings to fill
in or forward the questionnaire link to microbiology laboratories
within their specific countries.
Data collection
A set of multiple-choice questions was composed by the
CYSTINET members to collect the information for the present
study. Apart from some general information regarding labora-
tory and contact details, all questions referred to the current
activity of the laboratory in the field of T. solium and
T. saginata cysticercosis/taeniosis diagnostics. The question-
naire was pre-tested by CYSTINET laboratory members and
thereafter finalized (Supporting information, S1 File). Since the
questionnaire was composed by multiple-choice questions, the
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laboratory had to select the answer and if one was non-appli-
cable, the subsequent questions related to the former remained
closed. The internet-based questionnaire software SoSci
Survey [23] was used to gather the data. Every laboratory could
access the questionnaire with a link on the website www.
soscisurvey.de. Data was downloaded from the server and
processed using SPSS (SPSS Inc., released 2009, PASW
Statistics for Windows, version 18.0, Chicago).
There were no restrictions for laboratories to access the
questionnaire. All questionnaires were examined, including
those that were not completely filled in and those from labo-
ratories that did not agree to display their contact details. For
duplicate entries, the duplicate with the least information was
discarded. All answers were included anonymously in the
study. Table 1 summarizes the main questions answered by
the participant laboratories.
Based on the obtained information, an interactive map with
the different institutions carrying out the diagnosis of the dis-
eases in each country that agreed to display their information
was made available through the COST action website (http://
projects.cbra.be/cystinet/).
Results
From August 2014 to February 2016, 160 laboratories filled in
the questionnaire, but only 139 laboratories agreed to have their
input published (Table 1). The respondents were from 16
European countries, with Spain being the country from which
most responses (n = 117) were received (Fig. 1). Most of the
laboratories were microbiology laboratories. Few of them were
research laboratories, which also work as reference laboratories
and/or public health institutions in their countries; therefore,
they also have to support other laboratories for specific prob-
lems, such as taeniosis/cysticercosis diagnosis, Trichinella out-
breaks, cystic echinococcosis diagnosis, etc.
T. solium and T. saginata taeniosis diagnosis
Stool and proglottids were declared to be the samples mainly
tested for the taeniosis diagnosis (Table 2A). Seventy-six lab-
oratories (48%) stated that they handled T. solium and
T. saginata taeniosis suspected samples in the same way and
used the same tests, whereas eight (5%) laboratories declared
Table 1 Questionnaire composed by a set of multiple-choice questions to collect information about the current activity of the laboratory in the field of
T. solium and T. saginata cysticercosis/taeniosis diseases
Questions Questions (cont.)
What kind of samples can you test for T. solium taeniosis? Do you use immunodiagnostic methods to approach T. solium cysticercosis?
What kind of samples can you test for T. saginata taeniosis? Do you perform a T. solium cysticercosis antibody test?
How do you handle T. saginata taeniosis suspected samples? Which antibody detecting methods do you use to approach T. solium
cysticercosis?
Do you perform a T. solium taeniosis test? Do you perform a T. solium cysticercosis antigen test?
Do you perform a T. saginata taeniosis test? What kind of antigen do you use in your in-house antibody detection test?
Do you use microscopic methods to approach T. solium taeniosis? Do you observe any relevant cross reactions in your cysticercosis antibody
tests?
Do you use molecular methods to approach T. solium taeniosis? Which antigen detection methods do you use to approach T. solium
cysticercosis?
Do you use immunodiagnostic methods to approach T. solium
taeniosis?
What kind of antibodies do you use in your in-house test?
Do you observe any relevant cross reactions in your T. solium
taeniosis tests?
Do you observe any relevant cross reaction in your cysticercosis antigen tests?
If you use any other test for T. solium taeniosis suspected samples,
please specify
How do you evaluate sensitivity and specificity of your tests?
Do you use microscopic methods to approach T. saginata taeniosis? Are there national ring-trials in your country to ascertain the quality of your
T. solium and T. saginata tests?
Do you use molecular methods to approach T. saginata taeniosis? Would you be interested in participating in a European ring trial for T. solium
and T. saginata tests?
Do you use immunodiagnostic methods to approach T. saginata
taeniosis?
Do you have diagnostic tests for other Taenia spp. available?
Do you observe any relevant cross reactions in T. saginata taeniosis
tests?
Approximately howmany T. solium/saginata taeniosis or cysticercosis positive
samples did you have last year?
If you use any other test for T. saginata taeniosis suspected samples,
please specify
Do you refer T. solium/T.saginata cysticercosis or taeniosis samples to other
laboratories?
Which samples can you test for T. solium cysticercosis? Where do you refer the T. solium (neuro)cysticercosis suspicious samples to?
Do you use molecular methods to approach T. solium cysticercosis? Where do you refer the T. solium/saginata taeniosis suspicious samples to?
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they tested T. saginata and T. solium suspected samples, dif-
ferently. Seventy-four laboratories (46%) did not provide any
answer to this question.
Table 2B shows a summary of the tests used by the labo-
ratories. Eighty-seven (54%) laboratories declared to test for
taeniosis, whether caused by T. solium or T. saginata, but the
method used was not specified. However, 78 (49%) laborato-
ries stated the use of microscopy to diagnose taeniosis. The
search for T. solium eggs in fecal samples by a microscope
after stool concentration was carried out by 17 (22%) labora-
tories, one of which further used Ziehl-Neelsen staining [24].
Twenty-nine (37%) laboratories used stool concentration by
formalin-ether or formalin-acetate as well as microscopic ex-
amination of the proglottids after ink staining. Forty-one
(53%) laboratories reported to perform a microscopic exami-
nation of fresh fecal samples and a morphological identifica-
tion of the proglottids; moreover, one laboratory used
Carmine staining [25] and another declared to perform an
ELISA as well. Two laboratories declared to use the Kato-
Katz method; moreover, one of them reported to rely on his-
tology and the other one on the cellophane-tape test [25]. For
T. saginata taeniosis, five (50%) laboratories declared to per-
form stool concentration and two laboratories proglottid iden-
tification after ink staining [25].
Immunodiagnostic methods were declared to be used only
for T. solium taeniosis in 14 (9%) laboratories, from which 11
declared to use ELISA on serum samples or whole blood, two
western blot (WB) on serum samples and one ELISA plusWB
on serum and cerebral spinal fluid (CSF). Seventy-one (44%)
laboratories did not use any immunodiagnostic method to di-
agnose T. solium taeniosis and 75 (47%) did not provided any
information.
Molecular methods were applied to both stool and proglot-
tids by 15 laboratories. Nine (82%) laboratories employed
conventional PCR (c-PCR) alone, c-PCR or real time PCR
(RT-PCR) (one laboratory), and c-PCR and sequencing (two
laboratories) for the T. solium taeniosis diagnosis. For
T. saginata taeniosis, four laboratories declared using c-PCR.
Other Taenia spp. diagnosis
Twenty-six out of 160 (16%) laboratories reported the avail-
ability of diagnostic tests for other Taenia spp. Fifteen out of
26 (58%) declared microscopy as the diagnostic tool
employed. Two laboratories reported staining of the proglot-
tids, and seven used PCR for all Taenia spp.
T. solium (neuro)cysticercosis diagnosis
Serum and CSF were the preferred samples for T. solium
(neuro)cysticercosis diagnosis (Table 2A), although tissue
samples were also employed.
Fig. 1 Number of respondent
laboratories to the questionnaire
survey among European Union
member states and associated
countries
S1 File. Diagnostic questionnaire
(PDF).
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For T. solium (neuro)cysticercosis (Table 2B), 32 (20%) lab-
oratories declared using immunodiagnostic methods based on
antibody detection, and of those only three reported the use of
antigen detection methods as well. Nine (28%) out of 32 labo-
ratories used Bin-house^ ELISAs, from which six laboratories
used crude extracts from whole cysticerci, three used cyst fluid,
and one recombinant antigens as coating antigens. Commercial
ELISAwere from 11 companies and WB from five companies,
kits were used by 28 and 14 laboratories, respectively. Indirect
immuno-fluorescence assay (IFA) was employed by two labora-
tories, from which one declared using an Bin house^ IFA. An
Bin-house^ antigen detection method for NCC, based on the
monoclonal antibody, was used by one laboratory, and two lab-
oratories stated using a commercial kit, whichwas specified only
by one laboratory (Ag/ELISA ApDia).
Twelve (8%) laboratories declared using molecular
methods for NCC; of them, nine (6%) used c-PCR and three
(2%) RT-PCR in house tests. Molecular methods were used
either on CSF (by two laboratories) or on cysts fluid (by one
laboratory); the other nine laboratories did not specify the
matrix used.
In addition, two (1.2%) out of 160 laboratories declared
performing diagnosis on both bovine and porcine samples
and 11 laboratories did not answer.
Performance of taeniosis/cysticercosis tests and quality
assurance
Fifteen (9%) laboratories underlined relevant cross reactions
in NCC antibody tests used, but the names of the kits were not
reported, whereas 15 (9%) did not observe cross reactions.
Cross reactions were observed with E. granulosus infection
(11 laboratories), Entamoeba histolytica (one laboratory),
Trichinella spp. (one laboratory), T. saginata (one laboratory)
and other non-specified helminths (three laboratories).
No cross reaction was observed in antigen detection
methods for T. soliumNCC. Forty (25%) laboratories reported
no cross reactions in T. solium taeniosis tests, eight (5%) de-
clared cross reactions with E. granulosus (two laboratories),
other non-specified helminths (two laboratories) and
Entamoeba spp. (one laboratory), or did not specify the cross
reactive antigens. Eight laboratories reported no cross reaction
Table 2 (A) Number of laboratories and samples matrices, and (B) Number of laboratories and specific tests used to establish a diagnosis of T. solium
(neuro)cysticercosis and T. solium/T. saginata taeniosis
A
Sample matrix tested T. solium
(neuro)cysticercosis
Taeniosis
T. solium T. saginata
Stool 0 81 10
Proglottids 0 73 10
Serum 38 28 1
Cerebrospinal fluid 28 6 0
Tissue 11 2 1
B
Tests Pathology
T. solium (neuro)cysticercosis Taeniosis
T. solium T. saginata
Non specified 87
Microscopy Stool concentration 17
Stool concentration and morphological identification of the proglottids 0 29 5
Fresh exam and morphological identification of the proglottids 0 41 2
Other (Kato-Katz) 0 2 0
Immunodiagnosis Antibody detection ELISA 31 12 0
WB 14 3 0
IFA 2 0 0
Antigen detection In house 1 0 0
Commercial 2 0 0
Molecular method c-PCR 9 11 4
RT-PCR 3 1 0
c-PCR + Sequencing 0 2 0
ELISA enzyme-linked immunosorbent assay,WBwestern blotting, IFA immuno-fluorescence assay, c-PCR conventional polymerase chain reaction, RT-
PCR real time polymerase chain reaction
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in T. saginata tests, but all of them correctly underlined being
unable to microscopically distinguish taeniid species by egg
morphology.
Thirty (19%) laboratories evaluated the specificity and sen-
sitivity of the tests relying on manufacturers’ information, 17
(11%) did an Bin-house^ evaluation and 10 (6%) performed
different procedures, i.e. external quality control (five labora-
tories), inter-laboratory exchange (one laboratory), and
literature-based evaluation (one laboratory). Fifty-six (35%)
laboratories reported that they did not perform any control,
and 17 (11%) laboratories ticked Bunknown^ with regard to
tests sensitivity and specificity.
Concerning collaborative studies, 33 (21%) laboratories
declared the existence of ring trials in their countries aimed
at ascertaining the quality of the T. solium and T. saginata
tests, although they did not confirm their participation. Eight
(24%) laboratories reported the ring trials to be organized by a
National Reference Laboratory and 16 by scientific societies.
Ninety-four (59%) laboratories stated lack of awareness of the
organization of ring trials in their countries and 34 did not
answer. Forty-four (28%) laboratories declared not being in-
terested in participating in a European ring trial for T. solium
and T. saginata tests; whereas, 92 (58%) laboratories were
interested in such a collaborative study, either for T. solium
and T. saginata tests (80 laboratories) or for T. solium (12
laboratories) tests alone. Twenty-five (16%) laboratories did
not provide any answer to this question.
Forty-eight (30%) laboratories reported refering all
T. solium/T. saginata taeniosis or T. solium NCC suspicious
samples to other laboratories. Sixty (37.5%) laboratories stat-
ed referring only some samples to other laboratories. Forty-
five (28%) laboratories declared to never refer samples to
other laboratories. Seven (4.3%) laboratories did not answer.
Sixty-nine (43.1%) laboratories referred T. solium NCC sus-
picious samples to a reference laboratory and 19 (11.9%) to
private laboratories. Seventy-five (46.9%) and 12 (7.5%) lab-
oratories referred T. solium/T. saginata taeniosis suspicious
samples to a reference laboratory, or to private laboratories,
respectively.
The reported reference laboratories were: (i) the Institute of
Tropical Medicine, Antwerp, in Belgium, (ii) the Statens
Serum Institut, København, in Denmark, (iii) the
Department of Infectious Diseases and Tropical Medicine,
University Hospital Ludwig-Maximilians-Universität,
Munich, and Bernhard-Nocht Institute for Tropical
Medicine, Hamburg, in Germany, (iv) the Istituto Superiore
di Sanità, Rome, in Italy, (v) the Mikrobiologisk Avdeling
Haukeland Universitetssykehus, Bergen, in Norway, (vi) the
Instituto de Salud Carlos III, Majadahonda; Hospital Miguel
Servet, Zaragoza; Hospital Universitario Virgen de la
Arrixaca, Murcia; Hospital Son Espases, Mallorca;
Laboratorio de Referencia de Catalunya, El Prat de
Llobregat; Hospital La Fe, and Hospital Clínico, Valencia;
Hospital Virgen de la Victoria, Málaga; Hospital de Basurto,
Bilbao, in Spain, (vii) the Clinical Hospital of Infectious
Diseases, Cluj-Napoca, in Romania, and (viii) the Hospital
for Tropical Diseases, London, in the United Kingdom.
Positive samples of taeniosis and cysticercosis diagnosed
during a one-year period
Twenty-four (15%) and 26 (16%) laboratories, tested NCC
and taeniosis samples in the previous year, respectively
(Table 3). Moreover, 54 (34%) laboratories declared to have
had T. saginata taeniosis samples in the same time interval.
Ninety (56%), 95 (59%) and 61 (38%) laboratories did not
receive any sample for NCC, T. solium taeniosis, and
T. saginata taeniosis, respectively, in the course of the previ-
ous year. The number of positive samples reported is shown in
Table 3. Fifteen (9%), 13 (8%) and 9 (6%) laboratories de-
clared being unaware of the number of NCC, T. solium
taeniosis, and T. saginata taeniosis positive samples received.
Discussion
The diagnosis of T. solium (neuro)cysticercosis/T. solium
taeniosis in immigrants and travelers from endemic regions,
and sporadic autochthonous cases, continue to be a problem in
the EU [12–14]. Moreover, T. saginata taeniosis persists, de-
spite systematic meat inspection (64/433/EEC directive) [18],
and the potential introduction of T. asiatica by immigrants and
travelers from south-East Asia [26, 27] complicates the sce-
nario. Since in vitro diagnostic tools are available for taeniosis
and cysticercosis (Tables 4 and 5), the question arises whether
laboratories from the EU are prepared to accurately diagnose
human NCC and taeniid infections. Therefore, a questionnaire
(Table 1) was prepared and distributed among EU laboratories
to determine the present status of diagnostic tools used for the
analysis of NCC, T. solium and T. saginata taeniosis.
The laboratories which filled in the questionnaire were ran-
domly distributed in the EU (Fig. 1); indeed, most responders
were from Spain (117 laboratories, 73%). Only one laboratory
from Austr ia , Slovenia, Serbia, Switzerland and
The Netherlands filled in the questionnaire. The high number
of responding laboratories from Spain could be explained by
an increasing interest on these pathologies due to the increase
in imported cases in this country. Overall, the variation in
responses could be due to (i) the different structure of health
systems in the countries, more or less centralized according to
the regions; (ii) lack of interest, due to the low number of cases
of taeniosis/(neuro)cysticercosis diagnosed in some countries;
(iii) problems with the adequacy of institutional servers, i.e.
the questionnaire rejected by some of them; and (iv) no an-
swer because of no proper distribution of the questionnaire.
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As expected, stool and proglottids are the predominant sam-
ples tested for taeniosis, whereas serum is mainly tested for
T. solium NCC. Several laboratories reported to employ tissue
and CSF for NCC and few for T. solium taeniosis, whereas one
laboratory stated testing biopsies and serum samples to diag-
nose T. saginata taeniosis (Table 2A). It must be stressed that
Table 3 Number of positive
T. solium (neuro)cysticercosis and
T. solium/T. saginata taeniosis
samples in the previous calendar
year declared by the participating
laboratories
Pathology Number of positive
cases in the last year
Number of
laboratories
Country
T. solium
(neuro)cysticercosis
Unknown 15 France, Norway, Romania, Spain
No cases 90 Belgium, Denmark, France, Germany,
Italy, FYROM, Norway, Portugal,
Spain, UK
1–5 18 Denmark, France, Germany, Spain, UK
6–10 5 Germany, Spain, The Netherlands
51–100 1 Spain
T. solium taeniosis Unknown 13 France, Germany, Norway, Romania,
Spain
No cases 95 Belgium, Denmark, France, Germany,
Italy, FYROM, Norway, Portugal,
Spain, The Netherlands, UK
1–5 23 Belgium, Germany, Serbia, Slovenia,
Spain, Switzerland, UK
6–10 2 Spain
11–50 1 Spain
T. saginata taeniosis Unknown 9 France, Norway, Rumania, Spain
No cases 61 Belgium, Germany, FYROM, Italy,
Portugal, Spain
1–5 50 Belgium, Denmark, France, Germany,
Norway, Spain, The Netherlands,
UK
6–10 4 Spain, UK
Table 4 In vitro diagnostic tools for taeniosis
Tools Samples Comments
Microscopy Feces (up to three specimens
in different days), proglottids
• Gravid proglottids (count of uterine lateral branches) can allow species-specific identification
of adult worms [25]. Taeniid eggs look identical irrespective of the species.
• Other alternatives are needed to carry out the species-specific diagnosis of T. solium tapeworm
carriers, when only taeniid eggs and/or poorly preserved proglottids are available.
Antibody detection Serum • Two recombinant antigens from T. solium adult worms (rTSES33 and rTSES38) [28] were
cloned and expressed; rTSES33 [29] showed the best performance.
Antigen detection Feces • Coproantigen detection allows the detection before patency and evaluation of effectiveness
of taenicidal treatment.
• There are polyclonal antibody systems that do not exhibit taeniid species-specificity, like the
enzyme linked immunosorbent assay (ELISA) for coproantigen [30] and/or the whole
worm extract (WWE)-ELISA [31]. The most recent WWE- excretory secretory -ELISA
[31] protocol showed a good sensitivity and an improved specificity for T. solium
coproantigen-detection.
DNA detection Feces, proglottids • Excellent sensitivity and specificity on proglottids and stool samples from patent infections.
The assay sensitivity will be related to the analytical sensitivity of the molecular target used
[32–34], and its reliability will increase with the number of stool specimens analyzed
(important to use an efficient DNA-extraction method for feces). It can also be applied to
dubious proglottids.
• Amplification protocols are the most used methods (PCRs), and are mainly based on the
sequence of repetitive DNA, ribosomal DNA, mitochondrial DNA, and Antigen 2 (Ag2)
gene [32–40]. Loop mediated isothermal amplification assays (LAMP) [41] could potentially
overcome infrastructure challenges for the use of molecular techniques in endemic areas.
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biopsies, CSF and tissue samples are not adequate for taeniosis
diagnosis [25]. These inadequate answers suggest that the ques-
tion was not properly formulated and could have misled the
participants, though the questionnaire was pre-tested; or it
could be explained by a misunderstanding of these parasitic
infections, with overlapping of the taeniid pathologies, or just
by the lack of expertise in the diagnosis of intestinal parasites.
In general, EU laboratories seem better prepared for
taeniosis diagnosis by microscopy than for (N)CC diagnosis
by immunoassays [66]. This difference, observed also in the
present study (Table 2B), could be explained by the low cost
of basic coprological parasitological diagnostics that are rou-
tinely performed for the diagnosis of intestinal helminths,
whereas Bcommercial^ immunodetection test kits for (N)CC
are expensive, have a limited shelf life, and are mainly avail-
able in laboratories, which receive a high number of requests
in this specific diagnostic field.
Serological assays for T. solium, T. saginata and T. asiatica
taeniosis diagnoses using recombinant antigens and immuno-
blots have been described [28, 67], but these assays are only
used in research institutes and have not been commercialized yet.
Taeniosis
Forty-eight percent of the respondent laboratories stated han-
dling and processing T. solium and T. saginata taeniosis
suspected samples in the same way with the same techniques,
whereas 5% declared processing T. saginata and T. solium
suspected samples differently. These data might indicate
unawareness of the risk for the analysts in processing fecal
samples potentially containing T. solium eggs. Containment
Level 2 facilities, equipment, and operational practices are
needed [68, 69].
With respect to the methodology employed for taeniosis
diagnosis, as indicated above, microscopic methods were the
option most frequently chosen as opposed to immunodiagnos-
tic or DNA methods that were used in few laboratories only
(Table 4). Copro-antigen detection was used mainly in re-
search laboratories as this technique is not commercially avail-
able. Although copro-antigen detection is considered more
sensitive than microscopy, its specificity is still a matter of
debate [39, 70].
It is important to stress the relevance of molecular tech-
niques for taeniid species identification [32, 34, 35]. In the
case of feces containing eggs or proglottids, genomic amplifi-
cation is the preferred diagnostic option for a differential iden-
tification and the best way to recognize T. solium carriers [39].
However, only few (7, 4.3%) laboratories reported to have
molecular tools to distinguish the three Taenia spp. infecting
humans [40, 71]. Identification at the species level is crucial
because T. solium tapeworm carriers pose an immediate threat
to themselves, their household members and close contacts.
The diagnosis will determine the tapeworm-carrier manage-
ment that should include treatment, parasite collection, and
testing for NCC of both carrier and contacts. In the case of
T. saginata tapeworm carriers, their management should in-
clude treatment, and safe disposal of the tapeworm collected
to avoid environmental contamination leading to bovine
Table 5 In vitro diagnostic tools for cysticercosis
Tools Samples Comments
Microscopy Biopsy • Tissue examination by microscopy for the presence of suckers and hooks on the scolex [25].
Antibody detection Serum, cerebrospinal
fluid (CSF)
• Antibody detection in serum is the first option used in laboratories for neurocysticercosis (NCC)
diagnosis. Antibodies indicate parasite-exposure and work better with active NCC in comparison
to inactive NCC [42].
• Native antigens: the enzyme-linked immunoelectrotransfer blot (EITB) [43] assay with an
affinity-purified lentil-lectin glycoprotein fraction (LLGP), used as antigens, is the gold-standard
for NCC serodiagnosis.
• Recombinant antigens and synthetic peptides: many genes encoding diagnostic antigens were
described during recent decades [44–52], including the seven components of the LLGP fraction.
They were cloned and expressed as recombinant proteins in both prokaryotic and eukaryotic
systems, and evaluated using enzyme linked immunosorbent assay (ELISA), western blot (WB),
immunochromatography, and others [53].
The most promising antigens are members of the 8 kDa diagnostic antigen family [44, 46, 50], used
as fusion proteins/peptides, and recombinant proteins derived from the glycoproteins GPT24 and
GP50 [47, 49, 54], employed independently or as Bantigen cocktail^.
Antigen detection CSF, serum • The antigen-capture ELISAs based on the use of HP10 [55–57] or B158/B60 [58–61] monoclonal
antibodies, prepared against T. saginata antigens, are the two diagnostic options employed in both
detection and follow-up of NCC patients, mainly in patients with several active cysts and
extraparenchymal locations, and in epidemiological studies in endemic regions.
DNA detection CSF, biopsy • The amplification protocols (polymerase chain reaction, PCR) are the same described for the taeniosis
diagnosis (Table 4), but applied to CSF as clinical sample. So far, the amplification of pTsol9
repetitive sequence, in both conventional and real time PCR, and the seminested-HDP2-PCR, have
already been used in NCC case identification [62–65].
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infections. Considering the relevance of the species-specific
identification, multiplexed amplification protocols [37] would
be advisable, to avoid false negative results.
With regard to microscopy, only 21% of laboratories reported
their participation in ring-trials, organized by National Reference
Laboratories and Scientific Societies, to follow-up quality stan-
dards (http://www.instand-ev.de/en/news.html (INSTAND),
Sociedad Española de Infección y Microbiología Clínica
(SEIMC), Sociedad Valenciana de Microbiología Clínica
(SVAMC), Norwegian Nasjonalt Folkehelseinstituttet (FHI)).
These figures are low and they suggest the need for well-
organized collaborative studies to evaluate the performance of
taeniosis tests used by EU laboratories.
Neurocysticercosis
Immunodiagnostic methods were employed by most of the
laboratories rather than microscopy on biopsy samples or
DNA detection methods for NCC (Table 5). Many laboratories
used more than one test, frequently commercial kits, and few
employed Bin-house^ assays [43, 72]. Regarding the specificity
of these techniques, some laboratories highlighted relevant
cross-reactions, with both protozoa and certain helminth spe-
cies [73, 74], indicating no proper evaluation of the immuno-
logical tests used. Therefore, serological-ring trials with well-
characterized clinical samples would be needed to determine
the performances of the immunodiagnostic kits, to harmonize
and standardize their use, and finally to know more about the
real clinical significance of the immunodiagnostic tests
employed for NCC [10, 54, 75]. Within immunodiagnostic
methods, antigen-capture assays to diagnoseNCC are a specific
tool, mainly used on CSF. Among others, these assays allow
identification and follow-up of complicated NCC infections
[57, 76]. So far, the two options available were developed by
European groups, the HP10 and the B158/B60 monoclonal
antibody systems [77, 78], and are used for routine diagnosis
and in epidemiological studies in endemic regions [60, 79].
Molecular techniques show a relevant sensitivity and ex-
cellent specificity in both taeniosis and NCC diagnosis, using
different sample matrices such as CSF or tissue [40, 71].
However, the limited number of cases, lack of commercial
kits and working infrastructure limit their use today.
In general, the number of positive NCC and T. solium/
T. saginata taeniosis samples in the previous calendar year
declared by the participating laboratories was low (Table 3).
One laboratory from Spain reported the highest number of
NCC and T. solium taeniosis cases (ranges from 51 to 100
and from 11 to 50, respectively). These data could indicate
why the number of respondent laboratories was higher in
Spain than in other European countries, because in this coun-
try the high number of Latin American immigrants could lead
to an increased awareness and interest on the risk of imported
T. solium human cases.
The implementation of routine ring trials, as some labora-
tories have already done, could be necessary to improve the
standard quality level. In the case of NCC, a limited number
(32, 20%) of laboratories use commercial kits and only few (9,
28%) of them use Bin-house^ tests that would require valida-
tion by well-organized collaborative studies.
Overall, there seem to be only a few (15, 9.3%) laboratories
that have appropriate tools (all in vitro diagnostic approaches,
includingmicroscopy, and immunological andmolecular assays)
to identify T. solium taeniosis/NCC, which usually are located in
European regions where T. solium taeniosis/NCC used to be
endemic, where there is a strong travel/immigration pressure
and/or where there are close relations with endemic areas by
scientific networks. The results presented here are based on the
replies of the participating laboratories, which were not evenly
distributed over the involved countries, and as such the high
number of laboratories responding from Spain has an influence
on the results. The information obtained about the taeniosis/NCC
tests used in the laboratories will be a valuable contribution for
microbiology units to find support when they need it.
In addition, we suggest refreshing the knowledge on
T. solium taeniosis/NCC infections as the prevalence of the
disease seems rather low in Europe despite the fact that there
is some evidence that NCC may actually be on the rise [80].
Some laboratories highlighted that they did not see cases any-
more; however, we must be alert and ready for their diagnosis
and surveillance. In the case of T. saginata infections, similar
initiatives (e.g., knowledge refreshing on parasite transmis-
sion, risk factors, good practices, diagnostic tools) need to
be applied, as T. saginata taeniosis persists in the EU countries
despite an integrated approach among all stakeholders [18].
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